JP2026015500A5 - - Google Patents
Info
- Publication number
- JP2026015500A5 JP2026015500A5 JP2025194419A JP2025194419A JP2026015500A5 JP 2026015500 A5 JP2026015500 A5 JP 2026015500A5 JP 2025194419 A JP2025194419 A JP 2025194419A JP 2025194419 A JP2025194419 A JP 2025194419A JP 2026015500 A5 JP2026015500 A5 JP 2026015500A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- antibody
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105286 | 2020-07-28 | ||
| CN2020105286 | 2020-07-28 | ||
| CNPCT/CN2021/098476 | 2021-06-04 | ||
| CN2021098476 | 2021-06-04 | ||
| JP2023505901A JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| PCT/CN2021/108643 WO2022022503A1 (en) | 2020-07-28 | 2021-07-27 | Bifunctional molecules targeting pd-l1 and tgf-beta |
| JP2024187749A JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187749A Division JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026015500A JP2026015500A (ja) | 2026-01-29 |
| JP2026015500A5 true JP2026015500A5 (https=) | 2026-03-25 |
Family
ID=80037607
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505901A Withdrawn JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2024187749A Active JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2025194419A Pending JP2026015500A (ja) | 2020-07-28 | 2025-11-13 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505901A Withdrawn JP2023540436A (ja) | 2020-07-28 | 2021-07-27 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
| JP2024187749A Active JP7846734B2 (ja) | 2020-07-28 | 2024-10-24 | Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230287125A1 (https=) |
| EP (1) | EP4188950A4 (https=) |
| JP (3) | JP2023540436A (https=) |
| KR (1) | KR20230050356A (https=) |
| CN (4) | CN121319180A (https=) |
| AU (1) | AU2021317376A1 (https=) |
| IL (1) | IL299966A (https=) |
| PH (1) | PH12023550193A1 (https=) |
| WO (1) | WO2022022503A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026508210A (ja) * | 2023-02-20 | 2026-03-10 | 中山康方生物医▲藥▼有限公司 | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN108779180B (zh) * | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | 新型抗-pd-l1抗体 |
| EP3369745B1 (en) * | 2016-08-04 | 2021-09-29 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-pd-l1 nanobody and use thereof |
| EP3551659A1 (en) * | 2016-12-08 | 2019-10-16 | Eli Lilly and Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| AU2018264455B2 (en) * | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
| CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
| EP3470429A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
| CN109721657B (zh) * | 2017-10-27 | 2021-11-02 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
| JP7348899B2 (ja) * | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| WO2019185029A1 (en) * | 2018-03-29 | 2019-10-03 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| BR112021003093A2 (pt) * | 2018-08-22 | 2021-05-11 | Merck Patent Gmbh | tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta |
| US12559539B2 (en) * | 2018-11-09 | 2026-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta receptor fusion protein pharmaceutical composition and use thereof |
| US10851157B2 (en) * | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
| US11028174B1 (en) * | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| CN112940134B (zh) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | 针对PD-1和TGF-β的双功能蛋白 |
-
2021
- 2021-07-27 CN CN202511294608.4A patent/CN121319180A/zh active Pending
- 2021-07-27 US US18/007,265 patent/US20230287125A1/en active Pending
- 2021-07-27 PH PH1/2023/550193A patent/PH12023550193A1/en unknown
- 2021-07-27 CN CN202411428879.XA patent/CN119462927B/zh active Active
- 2021-07-27 EP EP21849817.8A patent/EP4188950A4/en active Pending
- 2021-07-27 AU AU2021317376A patent/AU2021317376A1/en not_active Abandoned
- 2021-07-27 CN CN202180061312.1A patent/CN116348493B/zh active Active
- 2021-07-27 IL IL299966A patent/IL299966A/en unknown
- 2021-07-27 KR KR1020237006251A patent/KR20230050356A/ko active Pending
- 2021-07-27 JP JP2023505901A patent/JP2023540436A/ja not_active Withdrawn
- 2021-07-27 CN CN202411428806.0A patent/CN119409832B/zh active Active
- 2021-07-27 WO PCT/CN2021/108643 patent/WO2022022503A1/en not_active Ceased
-
2024
- 2024-10-24 JP JP2024187749A patent/JP7846734B2/ja active Active
-
2025
- 2025-11-13 JP JP2025194419A patent/JP2026015500A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022101693A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2010535713A5 (https=) | ||
| JP2025109785A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2020522474A5 (https=) | ||
| JP2020527355A5 (https=) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2021511811A5 (https=) | ||
| JP2026015500A5 (https=) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2025069432A5 (https=) | ||
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2024016024A5 (https=) | ||
| JPWO2021155380A5 (https=) | ||
| JP2026041845A5 (https=) | ||
| JP2025092589A5 (https=) | ||
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| JP2021531255A5 (https=) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JPWO2022270524A5 (https=) | ||
| JP2024020436A5 (https=) |